EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30O: ONCOTHERAPY SCIENCE INC.

04 Sep 2026
LAST:

0.0905

CHANGE:
 0.01		OPEN:
0.0905		HIGH:
0.0905		ASK:
0.0000		VOLUME:
0
CHG(%):
7.91		PREV:
0.0885		LOW:
0.0905		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Sep 260.09050.09050.09050.09050
03 Sep 260.09550.09550.09550.09550
02 Sep 260.08850.08850.08850.08850
31 Aug 260.08850.08850.08850.08850
28 Aug 260.09350.09350.09350.09350
27 Aug 260.09350.09350.09350.09350
26 Aug 260.08300.08300.08300.08300
25 Aug 260.08800.08800.08800.08800
24 Aug 260.09350.09350.09350.09350
21 Aug 260.08800.08800.08800.08800

PROFILE

Name:ONCOTHERAPY SCIENCE INC.
About:OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Sector:Healthcare
Industry:Biotechnology
Address:1-2 Higashida-cho, Kawasaki, Japan, 210-0005
Website:https://www.oncotherapy.co.jp
ISIN:JP3202150003
LEI:529900CIAZCAIG781H52

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.03 
PEG Ratio:0.00 
Price to Sales:0.05 
Price to Book:2.76 
Profit Margin:-1.14 
Operating Margin:-1.68 
Return on Assets:-0.24 
Return on Equity:-0.52 
Revenue:4.19M 
Shares:277.64M 
Market Cap:25.13M 

TECHNICAL INDICATORS

MA5:0.091.5%
MA10:0.090.6%
MA20:0.093.9%
MA50:0.087.5%
MA100:0.091.8%
MA200:0.092.3%
STO9:100.00 
STO14:100.00 
RSI14:58.78
MTM14:0.01
ROC14:0.14 
ATR:0.00 
Week High:0.105.5%
Week Low:0.092.3%
Month High:0.105.5%
Month Low:0.082.3%
Year High:0.19112.2%
Year Low:0.0641.4%
Volatility:37.57